Citations (100)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Elisa Kankkunen, Patrick Penttilä, Katriina Peltola & Petri Bono. (2022) C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. Acta Oncologica 61:10, pages 1240-1247.
Read now
Read now
Cecilia Monge, Changqing Xie, Seth M Steinberg & Tim F Greten. (2021) Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 8, pages 507-512.
Read now
Read now
Articles from other publishers (98)
Paul Trinkner, Sophie Günther, Ina Monsef, Eva Kerschbaum, Michael von Bergwelt-Baildon, David M. Cordas dos Santos & Sebastian Theurich. (2023) Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis. European Journal of Cancer 184, pages 151-171.
Crossref
Crossref
Fukang Shi, Xing Huang, Zhengtao Hong, Na Lu, Xin Huang, Lingyue Liu, Tingbo Liang & Xueli Bai. (2023) Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. Cancer Letters 562, pages 216167.
Crossref
Crossref
Jiang-Min Zhou, Hui-Fang Xiong, Xiao-Ping Chen, Zhi-Wei Zhang, Li-Ping Zhu & Biao Wu. (2023) Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World Journal of Gastrointestinal Oncology 15:4, pages 689-699.
Crossref
Crossref
Wenhui Liu, Zhiying Luo, Yiping Liu & Bao Sun. (2023) Current landscape and tailored management of immune-related adverse events. Frontiers in Pharmacology 14.
Crossref
Crossref
Erick Rivera-Grana & Stephanie M. Llop. 2023. Eye Diseases - Recent Advances, New Perspectives and Therapeutic Options. Eye Diseases - Recent Advances, New Perspectives and Therapeutic Options.
Kavitha Palaniappan. (2023) Clinical Progress in Gold Nanoparticle (GNP)-mediated Photothermal
Cancer Therapy. Current Cancer Therapy Reviews 19:1, pages 13-18.
Crossref
Crossref
You-Cheng Zhang, Tian-Chen Zhu, Run-Cong Nie, Liang-He Lu, Zhi-Cheng Xiang, Dan Xie, Rong-Zhen Luo & Mu-Yan Cai. (2023) Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors. Journal of Clinical Medicine 12:3, pages 736.
Crossref
Crossref
Heran Deng, Liying Wang, Na Wang, Kejin Zhang, Yanxia Zhao, Pengfei Qiu, Xiaowei Qi, Danhua Zhang, Fei Xu & Jieqiong Liu. (2023) Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. BMC Cancer 23:1.
Crossref
Crossref
Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios & Michalis V. Karamouzis. (2023) Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers 15:2, pages 375.
Crossref
Crossref
Qiong Zhao, Luwen Zhang, Qiufen He, Hui Chang, Zhiqiang Wang, Hongcui Cao, Ying Zhou, Ruolang Pan & Ye Chen. (2023) Targeting TRMT5 suppresses hepatocellular carcinoma progression via inhibiting the HIF-1α pathways靶向TRMT5抑制HIF-1α信号通路调控肝癌进程. Journal of Zhejiang University-SCIENCE B 24:1, pages 50-63.
Crossref
Crossref
Wolf H. Fridman, Sophie Sibéril, Guilhem Pupier, Sarah Soussan & Catherine Sautès-Fridman. (2023) Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?. Seminars in Immunology 65, pages 101703.
Crossref
Crossref
Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. Weirather, Anita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon & William E. Gillanders. (2022) A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. npj Breast Cancer 8:1.
Crossref
Crossref
Ying-Yi Lin, Hong-Fei Gao, Xin Yang, Teng Zhu, Xing-xing Zheng, Fei Ji, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Jie-Qing Li, Min-Yi Cheng & Kun Wang. (2022) Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. The Breast 66, pages 126-135.
Crossref
Crossref
Penghui He, Haifeng Wan, Juan Wan, Hanyu Jiang, Yu Yang, Kunlin Xie & Hong Wu. (2022) Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Frontiers in Oncology 12.
Crossref
Crossref
Kimberly M. Winges & Lynn K. Gordon. (2022) Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions. Frontiers in Ophthalmology 2.
Crossref
Crossref
Xiaoyun Zhang, Shuo Xu, Jiaqi Wang, Yalei Lv, Na Wang, Ruixue Lai, Ziyue Sha, Qun Zhao & Zhanjun Guo. (2022) Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?. BMC Cancer 22:1.
Crossref
Crossref
Hikari Otsuka, Yuki Kita, Katsuhiro Ito, Takeshi Sano, Junichi Inokuchi, Ryotaro Tomida, Atsushi Takahashi, Kazumasa Matsumoto, Ryoma Kurahashi, Yu Ozaki, Masayuki Uegaki, Satoru Maruyama, Shoichiro Mukai, Masakazu Tsutsumi, Takashi Kawahara, Takehiko Segawa, Hiroshi Kitamura, Satoshi Morita & Takashi Kobayashi. (2022) Immune‐related adverse events in urothelial cancer patients: Adjustment for immortal time bias. Cancer Science 113:11, pages 3912-3921.
Crossref
Crossref
Alice Tison, Soizic Garaud, Laurent Chiche, Divi Cornec & Marie Kostine. (2022) Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nature Reviews Rheumatology 18:11, pages 641-656.
Crossref
Crossref
Salma El-Behaedi, Spencer Ng, Parul K. Goyal & Jennifer N. Choi. (2022) Widespread cutaneous eruption following COVID-19 vaccine in the setting of immunotherapy. JAAD Case Reports 29, pages 48-50.
Crossref
Crossref
François Deharo, Julien Carvelli, Jennifer Cautela, Maxime Garcia, Claire Sarles, Andre Maues de Paula, Jérémy Bourenne, Marc Gainnier & Amandine Bichon. (2022) Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. Journal of Clinical Medicine 11:19, pages 5611.
Crossref
Crossref
Dawson Foster, Imad Karam, Sri Nadella, Deborah Adekunle, Margaret Meyer, Merra Rana & Joseph Sokhn. (2022) A Therapy-Terminating Event: Programmed Death-1 Inhibitor-Induced Mucositis. Cureus.
Crossref
Crossref
Lu Yu, Minghan Sun, Qi Zhang, Qiao Zhou & Yi Wang. (2022) Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Christos SACHPEKIDIS, Jessica C. HASSEL & Antonia DIMITRAKOPOULOU-STRAUSS. (2022) Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 66:3.
Crossref
Crossref
Benjamin C. Park, Seungyeon Jung, Steven T. Chen, Anna K. Dewan & Douglas B. Johnson. (2022) Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. American Journal of Clinical Dermatology 23:5, pages 707-717.
Crossref
Crossref
Elia Seguí, Carles Zamora-Martínez, Tanny Daniela Barreto, Joan Padrosa, Margarita Viladot & Javier Marco-Hernández. (2022) Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. Diagnostics 12:9, pages 2116.
Crossref
Crossref
Tomoyo Kubo, Akihisa Hino, Kentaro Fukushima, Yoshimitsu Shimomura, Masako Kurashige, Shinsuke Kusakabe, Yasuhiro Nagate, Jiro Fujita, Takafumi Yokota, Hisashi Kato, Hirohiko Shibayama, Atsushi Tanemura & Naoki Hosen. (2022) Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report. International Journal of Hematology 116:2, pages 302-306.
Crossref
Crossref
An-Tian Chen, Yue-Quan Shi, Bei Tan, Liang Zhu, Ya-Ping Luo, Wei Zhong, Meng-Zhao Wang & Yan Xu. (2022) Case Report: A Programmed Cell Death-1 Inhibitor-Related Abdominal Fibroinflammatory Reaction Affecting Multiple Organs in A Non-Small-Cell Lung Cancer Patient. Frontiers in Immunology 13.
Crossref
Crossref
Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, Md. Noor Alam, Md. Mohaimenul Islam, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya & Simona Gabriela Bungau. (2022) Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules 27:12, pages 3798.
Crossref
Crossref
Genoveffa Nuzzo, Giuseppina Senese, Carmela Gallo, Federica Albiani, Lucia Romano, Giuliana d’Ippolito, Emiliano Manzo & Angelo Fontana. (2022) Antitumor Potential of Immunomodulatory Natural Products. Marine Drugs 20:6, pages 386.
Crossref
Crossref
Iñigo Les, Inés Pérez-Francisco, María Cabero, Cristina Sánchez, María Hidalgo, Lucía Teijeira, Virginia Arrazubi, Severina Domínguez, Pilar Anaut, Saioa Eguiluz, Iñaki Elejalde, Alberto Herrera & Mireia Martínez. (2022) Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. Frontiers in Pharmacology 13.
Crossref
Crossref
Daniel V. Araujo, Bruno Uchoa, Juan José Soto-Castillo, Larissa L. Furlan & Marc Oliva. (2022) When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Targeted Oncology 17:3, pages 253-270.
Crossref
Crossref
Kenji Ishido, Satoshi Tanabe, Chikatoshi Katada, Yu Ishibashi, Gen Kitahara, Mie Onoue, Yo Kubota, Yasuaki Furue, Takuya Wada, Akinori Watanabe & Chika Kusano. (2022) Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab. Journal of Gastrointestinal Cancer.
Crossref
Crossref
T. Anders Olsen, Tony Zibo Zhuang, Sarah Caulfield, Dylan J. Martini, Jacqueline T. Brown, Bradley C. Carthon, Omer Kucuk, Wayne Harris, Mehmet Asim Bilen & Bassel Nazha. (2022) Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Frontiers in Endocrinology 13.
Crossref
Crossref
Marion Allouchery, Clément Beuvon, Marie-Christine Pérault-Pochat, Pascal Roblot, Mathieu Puyade & Mickaël Martin. (2022) Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers 14:4, pages 955.
Crossref
Crossref
Peter SchmidJavier Cortes, Rebecca DentLajos PusztaiHeather McArthurSherko KümmelJonas BerghCarsten DenkertYeon Hee Park, Rina HuiNadia HarbeckMasato Takahashi, Michael UntchPeter A. FaschingFatima CardosoJay AndersenDebra PattMichael DansoMarta FerreiraMarie-Ange Mouret-ReynierSeock-Ah ImJin-Hee AhnMaria GionSally Baron-HayJean-François BoileauYu DingKonstantinos TryfonidisGursel AktanVassiliki KarantzaJoyce O’Shaughnessy. (2022) Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine 386:6, pages 556-567.
Crossref
Crossref
Yuequan Shi, Jian Fang, Chengzhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu & Mengzhao Wang. (2021)
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in
China
. Thoracic Cancer 13:3, pages 412-422.
Crossref
Crossref
Clémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, Laurent Mortier, Sophie Dalac-Rat, Caroline Dutriaux, Delphine Legoupil, Henri Montaudié, Olivier Dereure, Julie De Quatrebarbes, Florence Granel-Brocard, Myrtille Le-Bouar, Julie Charles, Florence Brunet-Possenti, Brigitte Dreno, Wendy Lefevre, Clara Allayous, Céleste Lebbe & Charlée Nardin. (2022) Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort. Journal of the American Academy of Dermatology 86:2, pages 345-352.
Crossref
Crossref
Kathleen M. Capaccione, Sophia Huang, Zeeshan Toor, Benjamin May, Aileen Deng & Mary M. Salvatore. (2022) Immunotherapy related pericardial effusion on chest CT. Clinical Imaging 82, pages 204-209.
Crossref
Crossref
Alejandra Flores-Chávez, Pilar Brito-Zerón, Soledad Retamozo, Samuel Bitoun, Benjamin A. Fisher, David Liew, Karijn Suijkerbuijk, Katerina Chatzidionysiou, María Suárez-Almazor, Olivier Lambotte, Xavier Mariette & Manuel Ramos-Casals. (2022) Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective. Critical Reviews in Immunology 42:4, pages 21-36.
Crossref
Crossref
Wanying Zhao, Yuanzheng Liang & Liang Wang. (2021) Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. Aging Pathobiology and Therapeutics 3:4, pages 84-94.
Crossref
Crossref
Eungjun Yoon, Tae Yeul Kim, Sun Kyoung Mun & Duck Cho. (2021) Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors. The Korean Journal of Blood Transfusion 32:3, pages 201-208.
Crossref
Crossref
Sihui Zhu, Lijuan Bian, Jia Lv, Baorui Liu & Jie Shen. (2021) A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors. Frontiers in Immunology 12.
Crossref
Crossref
Jacobi Hines, Ellen Daily, Anh Khoa Pham, Christopher R. Shea, Urooba Nadeem, Aliya N. Husain, Walter M. Stadler & Pankti Reid. (2021) Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. Journal of Medical Case Reports 15:1.
Crossref
Crossref
Terri Shih, Shawn Shih & Mohammad Sharaf. (2021) Pembrolizumab‐induced erythema multiforme requiring systemic immunosuppression. Internal Medicine Journal 51:12, pages 2149-2150.
Crossref
Crossref
Courtney H. Coschi & Rosalyn A. Juergens. (2021) The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. Current Oncology 28:6, pages 4392-4407.
Crossref
Crossref
Erica S Tsang, Evan J Walker, Julia Carnevale, George A Fisher & Andrew H Ko. (2021) Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Immunotherapy 13:15, pages 1249-1254.
Crossref
Crossref
Carolina A. Ferreira, Pedram Heidari, Bahar Ataeinia, Nicoleta Sinevici, Meghan E. Sise, Robert B. Colvin, Eric Wehrenberg-Klee & Umar Mahmood. (2021) Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical Cancer Research 27:19, pages 5353-5364.
Crossref
Crossref
Henry T. Quach, Douglas B. Johnson, Nicole R. LeBoeuf, Jeffrey P. Zwerner & Anna K. Dewan. (2021) Cutaneous adverse events caused by immune checkpoint inhibitors. Journal of the American Academy of Dermatology 85:4, pages 956-966.
Crossref
Crossref
A. Sibille, M. Henket, J. L. Corhay, R. Alfieri, R. Louis & B. Duysinx. (2021) White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung 199:5, pages 549-557.
Crossref
Crossref
Xiaoyan Zhang, Dongjiang Sui, Dong Wang, Lina Zhang & Ruiyan Wang. (2021) Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid. Frontiers in Immunology 12.
Crossref
Crossref
Tim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, Austin G Duffy, Anthony B. El-Khoueiry, Richard S Finn, Peter R Galle, Lipika Goyal, Aiwu Ruth He, Ahmed O Kaseb, Robin Kate Kelley, Riccardo Lencioni, Amaia Lujambio, Donna Mabry Hrones, David J Pinato, Bruno Sangro, Roberto I Troisi, Andrea Wilson Woods, Thomas Yau, Andrew X Zhu & Ignacio Melero. (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 9:9, pages e002794.
Crossref
Crossref
Elizabeth R. Berger, Tristen Park, Angeleke Saridakis, Mehra Golshan, Rachel A. Greenup & Nita Ahuja. (2021) Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals 14:8, pages 763.
Crossref
Crossref
Sophie L. Duong, Sarah Zierold, Rafaela Kramer, Martin Reincke, Katrin Kerl-French, Wolfgang Boehmerle, Marianne Pavel, Ludwig Weckbach, Lars E. French, Samuel Knauss & Lucie Heinzerling. (2021) Spätfolgen nach ImmuntherapieSequelae of immunotherapy. Der Onkologe 27:8, pages 739-746.
Crossref
Crossref
Keitaro Shimozaki, Yasutaka Sukawa, Yasunori Sato, Sara Horie, Akihiko Chida, Kai Tsugaru, Kazuhiro Togasaki, Kenta Kawasaki, Kenro Hirata, Hideyuki Hayashi, Yasuo Hamamoto & Takanori Kanai. (2021) Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncology 17:20, pages 2593-2603.
Crossref
Crossref
Sang Jun Yoon, Chae Bin Lee, Soon Uk Chae, Seong Jun Jo & Soo Kyung Bae. (2021) The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. International Journal of Molecular Sciences 22:13, pages 6932.
Crossref
Crossref
Ryan G. Holstead, Baskoro A. Kartolo, Wilma M. Hopman & Tara D. Baetz. (2021) Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Research 31:3, pages 258-263.
Crossref
Crossref
Raphael E. Huntley, Katherine DeNiro, Jardin Yousef, Meredith Sheedy & Jasjit K. Dillon. (2021) Severe Mucositis Secondary to Pembrolizumab: Reports of Two Cases, Review of the Literature, and an Algorithm for Management. Journal of Oral and Maxillofacial Surgery 79:6, pages 1262-1269.
Crossref
Crossref
B. Gülave, M.N. Hew, J.S. de Groot, L. Rodwell, S. Teerenstra & B.O. Fabriek. (2021) High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors. ESMO Open 6:3, pages 100107.
Crossref
Crossref
Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, Gil Awada, Valérie Vandersleyen, Sandrine Aspeslagh & Bart Neyns. (2021) C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Research Publish Ahead of Print.
Crossref
Crossref
Victoria Klepsch, Kerstin Siegmund & Gottfried Baier. (2021) Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6. Cancers 13:11, pages 2600.
Crossref
Crossref
Idoroenyi Amanam, Rohan Gupta, Vinod Pullarkat & Matthew Mei. (2021) Immune thrombocytopenia after immune checkpoint inhibitor therapy. British Journal of Haematology 193:3, pages 677-681.
Crossref
Crossref
Chunlan Wu, Li Zhong, Qing Wu, Shaowei Lin & Xianhe Xie. (2021) The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. Immunotherapy 13:6, pages 527-539.
Crossref
Crossref
Aneesha Ahluwalia & Anita A. Kohli. (2021) Photopsias in the Setting of Nivolumab Therapy. Journal of Neuro-Ophthalmology 41:1, pages e25-e26.
Crossref
Crossref
Agnese Paderi, Roberta Giorgione, Elisa Giommoni, Marinella Mela, Virginia Rossi, Laura Doni, Andrea Minervini, Marco Carini, Serena Pillozzi & Lorenzo Antonuzzo. (2021) Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers 13:4, pages 860.
Crossref
Crossref
Nikhila Kethireddy, Steffi Thomas, Poorva Bindal, Prateek Shukla & Upendra Hegde. (2020) Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab. Journal of Oncology Pharmacy Practice 27:1, pages 207-211.
Crossref
Crossref
Muhammad Ashar Ali, Wajeeha Aiman, Syed S. Shah, Mahreen Hussain & Richi Kashyap. (2021) Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials. Critical Reviews in Oncology/Hematology 157, pages 103197.
Crossref
Crossref
R. Park, L. Lopes & A. Saeed. (2020) Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Clinical and Translational Oncology 23:1, pages 100-109.
Crossref
Crossref
Muhammad Aamir Hassan, Aqib Zafar Khan, Muhammad Munir Sajid, Yasir Javed, Asmat Ullah, Naveed Akhtar Shad, Surender K. Sharma, Muhammad Shafique & Muhammad Sarwar. 2021. Spinel Nanoferrites. Spinel Nanoferrites
101
128
.
Pritha Sharma, Martin Barnes, Shaha Nabeel & William LiPera. (2020) Pembrolizumab-Induced Bullous Pemphigoid Treated With Rituximab. JCO Oncology Practice 16:11, pages 764-766.
Crossref
Crossref
Kelsey Sheehan, Christina Price & Navid Hafez. (2020) Optimizing Care for Patients With Adverse Events From Immunotherapeutics. The Cancer Journal 26:6, pages 537-542.
Crossref
Crossref
Lotte K. Kristensen, Camilla Christensen, Maria Z. Alfsen, Sigrid Cold, Carsten H. Nielsen & Andreas Kjaer. (2020) Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging. Molecular Imaging and Biology 22:4, pages 1021-1030.
Crossref
Crossref
Steffi Thomas, Chay Bae, Tabanor Joy-Ann & William Traverse. (2019) Behcet’s-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy. Journal of Oncology Pharmacy Practice 26:4, pages 995-999.
Crossref
Crossref
Cory Kosche, Molly Stout, Jeffrey Sosman, Rimas V. Lukas & Jennifer N. Choi. (2020) Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. Melanoma Research 30:3, pages 313-316.
Crossref
Crossref
Manuel Ramos-Casals, Julie R. Brahmer, Margaret K. Callahan, Alejandra Flores-Chávez, Niamh Keegan, Munther A. Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat & Maria E. Suárez-Almazor. (2020) Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers 6:1.
Crossref
Crossref
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila & José Antonio Gil‐Montoya. (2019) An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. Oral Diseases 26:3, pages 511-526.
Crossref
Crossref
Rhiane Moody, Kirsty Wilson, Anthony Jaworowski & Magdalena Plebanski. (2020) Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. Cancers 12:3, pages 673.
Crossref
Crossref
Karen A. Autio, Valentina Boni, Rachel W. Humphrey & Aung Naing. (2020) Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clinical Cancer Research 26:5, pages 984-989.
Crossref
Crossref
Peter SchmidJavier CortesLajos PusztaiHeather McArthurSherko KümmelJonas BerghCarsten DenkertYeon Hee Park, Rina HuiNadia HarbeckMasato Takahashi, Theodoros Foukakis, Peter A. FaschingFatima CardosoMichael UntchLiyi JiaVassiliki KarantzaJing ZhaoGursel AktanRebecca DentJoyce O’Shaughnessy. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine 382:9, pages 810-821.
Crossref
Crossref
Satya Das & Douglas B. Johnson. (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Milena Music, Antoninus Soosaipillai, Ihor Batruch, Ioannis Prassas, Dimitrios P. Bogdanos & Eleftherios P. Diamandis. (2019) A proteome-wide immuno-mass spectrometric identification of serum autoantibodies. Clinical Proteomics 16:1.
Crossref
Crossref
Nora Möhn, Gernot Beutel, Ralf Gutzmer, Philipp Ivanyi, Imke Satzger & Thomas Skripu. (2019) Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook. Journal of Clinical Medicine 8:11, pages 1777.
Crossref
Crossref
Nora Möhn, Kurt-Wolfram Sühs, Stefan Gingele, Yenny Angela, Martin Stangel, Ralf Gutzmer, Imke Satzger & Thomas Skripuletz. (2019) Acute progressive neuropathy–myositis–myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. Melanoma Research 29:4, pages 435-440.
Crossref
Crossref
Domenico Ribatti, Tiziana Annese, Simona Ruggieri, Roberto Tamma & Enrico Crivellato. (2019) Limitations of Anti-Angiogenic Treatment of Tumors. Translational Oncology 12:7, pages 981-986.
Crossref
Crossref
Anne Sibille, Romain Alfieri, Olivier Malaise, Nancy Detrembleur, Michelle Pirotte, Renaud Louis & Bernard Duysinx. (2019) Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer. Frontiers in Oncology 9.
Crossref
Crossref
Antonia Dimitrakopoulou-Strauss. (2018) Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT. Cancer Immunology, Immunotherapy 68:5, pages 813-822.
Crossref
Crossref
Anastasios Kyriazoglou, Michael Liontos, Costantinos Papadopoulos, Afroditi Bilali, Euthymios Kostouros, Stamatina Pagoni, Konstantinos Doumas, Meletios Athanasios Dimopoulos & Aristotelis Bamias. (2019) Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. Clinical Genitourinary Cancer 17:2, pages e360-e364.
Crossref
Crossref
Austin Doughty, Ashley Hoover, Elivia Layton, Cynthia Murray, Eric Howard & Wei Chen. (2019) Nanomaterial Applications in Photothermal Therapy for Cancer. Materials 12:5, pages 779.
Crossref
Crossref
Stefan E. G. Burdach, Mike-Andrew Westhoff, Maximilian Felix Steinhauser & Klaus-Michael Debatin. (2018) Precision medicine in pediatric oncology. Molecular and Cellular Pediatrics 5:1.
Crossref
Crossref
Cory Kosche, Nisha Mohindra & Jennifer N. Choi. (2018) Vitiligo in a patient undergoing nivolumab treatment for non–small cell lung cancer. JAAD Case Reports 4:10, pages 1042-1044.
Crossref
Crossref
Adriana T. Lopez & Larisa Geskin. (2018) A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. The Oncologist 23:10, pages 1119-1126.
Crossref
Crossref
Qiaoyun Tan, Shuxia Liu, Caixia Liang, Xiaohong Han & Yuankai Shi. (2018) Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis. Thoracic Cancer 9:10, pages 1220-1230.
Crossref
Crossref
Leonard H. Calabrese, Cassandra Calabrese & Laura C. Cappelli. (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nature Reviews Rheumatology 14:10, pages 569-579.
Crossref
Crossref
Milena Tocut, Ronen Brenner & Gisele Zandman-Goddard. (2018) Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmunity Reviews 17:6, pages 610-616.
Crossref
Crossref
Stefan ZimmermannSolange PetersTaofeek OwinokokoShirish M. Gadgeel. (2018) Immune Checkpoint Inhibitors in the Management of Lung Cancer. American Society of Clinical Oncology Educational Book:38, pages 682-695.
Crossref
Crossref
Antonio Riva & Shilpa Chokshi. (2018) Immune checkpoint receptors: homeostatic regulators of immunity. Hepatology International 12:3, pages 223-236.
Crossref
Crossref
Massimo Russo & Raffaella Giavazzi. (2018) Anti-angiogenesis for cancer: Current status and prospects. Thrombosis Research 164, pages S3-S6.
Crossref
Crossref
Bob Meek, Marcel P. H. van den Broek & Anouk C. M. Platteel. (2018) Biologicals: spectrum en targets. Bijblijven 34:2, pages 93-107.
Crossref
Crossref
Katherine Cook, Lindy Durrant & Victoria Brentville. (2018) Current Strategies to Enhance Anti-Tumour Immunity. Biomedicines 6:2, pages 37.
Crossref
Crossref